Fed Regist. 1999 Aug 19;64(160):45155-61.
The Food and Drug Administration (FDA) is issuing a final rule to require the filing of a premarket approval application (PMA) or a notice of completion of a product development protocol (PDP) for the silicone inflatable breast prosthesis, a generic type of medical device intended to augment or reconstruct the female breast. This device is made of a silicone shell that is inflated with sterile isotonic saline. Commercial distribution of this device must cease unless a manufacturer or importer has filed with FDA a PMA or PDP for its version of the silicone inflatable breast prosthesis within 90 days of the effective date of this regulation. This regulation reflects FDA's exercise of its discretion to require PMA's or PDP's for preamendments devices and is consistent with FDA's stated priorities and Congress' requirement that class III devices are to be regulated by FDA's premarket review. This action is being taken under the Federal Food, Drug, and Cosmetic Act (the act), as amended by the Medical Device Amendments of 1976 (the amendments), the Safe Medical Devices Act of 1990, and the Food and Drug Administration Modernization Act of 1997.
美国食品药品监督管理局(FDA)正在发布一项最终规定,要求提交上市前批准申请(PMA)或产品开发方案完成通知(PDP),用于硅酮可充气乳房假体,这是一种用于增大或重建女性乳房的通用型医疗器械。该器械由一个硅酮外壳构成,内部充有无菌等渗盐水。除非制造商或进口商在本规定生效日期起90天内向FDA提交其版本的硅酮可充气乳房假体的PMA或PDP,否则该器械的商业销售必须停止。本规定体现了FDA行使其酌处权,要求对修正案生效前的器械提交PMA或PDP,并且符合FDA既定的优先事项以及国会要求对III类器械进行FDA上市前审查的规定。本行动是依据经1976年《医疗器械修正案》(修正案)、1990年《安全医疗器械法案》以及1997年《食品药品管理局现代化法案》修订的《联邦食品、药品和化妆品法案》(该法案)采取的。